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Abstract
Background: Targeted drug-carrying phage nanomedicines are a new class of nanomedicines that combines
biological and chemical components into a modular nanometric drug delivery system. The core of the system is a
filamentous phage particle that is produced in the bacterial host Escherichia coli. Target specificity is provided by a
targeting moiety, usually an antibody that is displayed on the tip of the phage particle. A large drug payload is
chemically conjugated to the protein coat of the phage via a chemically or genetically engineered linker that
provides for controlled release of the drug after the particle homed to the target cell. Recently we have shown
that targeted drug-carrying phage nanomedicines can be used to eradicate pathogenic bacteria and cultured
tumor cells with great potentiation over the activity of the free untargeted drug. We have also shown that poorly
water soluble drugs can be efficiently conjugated to the phage coat by applying hydrophilic aminoglycosides as
branched solubility-enhancing linkers.
Results: With an intention to move to animal experimentation of efficacy, we tested anti-bacterial drug-carrying
phage nanomedicines for toxicity and immunogenicity and blood pharmacokinetics upon injection into mice. Here
we show that anti-bacterial drug-carrying phage nanomedicines that carry the antibiotic chloramphenicol
conjugated via an aminoglycoside linker are non-toxic to mice and are greatly reduced in immunogenicity in
comparison to native phage particles or particles to which the drug is conjugated directly and are cleared from
the blood more slowly in comparison to native phage particles.
Conclusion: Our results suggest that aminoglycosides may serve as branched solubility enhancing linkers for drug
conjugation that also provide for a better safety profile of the targeted nanomedicine.
Background
The majority of known anti-bacterial approaches are
based on the selectivity and potency of the antibiotic
molecule itself, excluding highly toxic and non-specific
therapeutics from the clinical application. The attaching
of a non-selective drug to the suitable targeted carrier
could provide specificity to the therapeutic complex and
may improve its physical and biological characteristics
such as solubility, cytotoxicity, circulation half-life and
distribution to certain tissues and cells.
This study continues the evaluation of an anti-bacterial
approach we have recently introduced that included the
application of the bacteriophage (phage) nanoparticle as
targeted, high-capacity anti-bacterial drug carriers [1,2]. In
this approach, the phage particle served as a drug-carrying
platform that was genetically and chemically modified to
display a targeting moiety (mostly an antibody) on its sur-
face and was used to deliver a large payload of a cytotoxic
drug to the target bacteria. The platform was based on the
f1 filamentous coliphage that was displaying anti-bacterial
peptide or antibody on the minor pIII coat protein. The
displayed protein provided the specific targeting to the
pathogen while the natural host specificity of the phage
was not relevant to its therapeutic potential. The cytotoxic
drug (chloramphenicol) was chemically modified to con-
tain an esterase cleavage-susceptible linker and was chemi-
cally conjugated to phage via a hydrophilic linker (the
aminoglycoside neomycin). The controlled (or in fact,
delayed) drug release was facilitated by serum esterases
activity. The targeted drug-loaded phage particle demon-
strated its ability to specifically recognize several model
bacterial pathogens and to inhibit their growth in vitro by
creating the high local drug concentration near the target
* Correspondence: benhar@post.tau.ac.il
Department of Molecular Microbiology and Biotechnology, The George S.
Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Israel
Vaks and Benhar Journal of Nanobiotechnology 2011, 9:58
http://www.jnanobiotechnology.com/content/9/1/58
© 2011 Vaks and Benhar; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.bacteria. The carrying capacity of phage particle was estab-
lished as 10,000 chloramphenicol molecules per phage and
the improvement factor of 20,000 in drug potency in com-
parison to the free drug had been observed [2].
When particulate nanoparticles are considered for in
vivo application, issues of pharmacokinetics, toxicity and
immunogenicity become relevant [3-5]. The objectives
o ft h i ss t u d yw e r et oe v a l u a t et h ein vivo characteristics
of targeted drug-carrying phage nanomedicines such as
toxicity, immunogenicity and pharmacokinetics and to
estimate the potential of phage-based drug-carrying
approach for in vivo application.
Results and discussion
Basic properties of Neo-CAM conjugated phages vs.
native phages
Conjugation of the drug chloramphenicol to the phage
coat proteins involves EDC (1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide) chemistry that is used to couple pri-
mary amines provided by the neomycin-chloramphenicol
prodrug to surface-exposed carboxyl groups on the phage
coat proteins. We found that the drug conjugation process
that affected all surface exposed coat proteins radically
influenced the basic phage characteristics - its ability to
infect its natural bacterial host. As shown in Figure 1, fol-
lowing Neo-CAM conjugation, the phages almost totally
lost their infectivity, with less than 0.00001% of drug carry-
ing phages kept its ability to infect its host (E. coli). This
can be regarded as an advantage, as one of the concerns in
classical phage therapy is that once introduced into the
body that (infective) phages may undergo replication
cycles resulting in their number becoming uncontrollable.
In addition, the antigenic profile of the phages was attenu-
ated as well, as the drug conjugation presumably affected
the epitopes on the phage surface that prevented the
phage recognition by a monoclonal anti-PVIII antibody
(Figure 1B). These were early indications that dramatic
changes in basic phage properties occurred following drug
conjugation to the surface of the phage particles, which
may influence their in vivo characteristics upon injection
into animals, such as toxicity and immunogenicity.
Neo-CAM carrying phages have low toxicity in vivo
Previous studies on phage therapy demonstrated that
when prepared properly, phage injection does not harm
animals or humans upon oral administration [6] and
minimal toxicity was detected in mice upon i.v. adminis-
tration to mice [7]. However, drug-carrying phages were
not evaluated in vivo before. We evaluated the toxicity
of Neo-CAM carrying bacteriophages to evaluate the
effect of conjugation of the drug with the serious toxic
characteristics. The mice received a single injection of
either native or of Neo-CAM conjugated phages at three
concentrations (10
9 (low), 10
10 (medium) and 10
11
(high) phage per dose). The intravenous as well as intra-
peritoneal administration routes were examined. The
mice weight and behavior were observed for 8 days fol-
lowed the injection. During the observation period the
mice showed no sign of distress or toxicity (no deaths
were recorded), and no weight loss nor behavioral
changes as a result of low and medium dose injections.
The high dose (10
11 phages) caused up to 2% and 6%
weight loss by Neo-CAM phage and by native phage,
respectively. Considering that the conjugated drug -
chloramphenicol has been reported as haemolytic upon
systemic injection [8], it was reassuring to observe that
the drug conjugated phages did not demonstrate drug-
related toxicity and even showed loss toxicity at high
dose in comparison to un-conjugated phages (Figure 2).
Neo-CAM carrying phages are less immunogenic than
unconjugated phages
The high immunogenicity of phages is a well-known
feature that limits the rapid development of phage-
Figure 1 The phage basic properties are influenced by drug
conjugation process. (A) The phage infectivity evaluation prior vs.
post drug conjugation by live titration. E. coli bacteria (TG-1 strain)
were used for infectivity determination. (B) The determination of the
phage recognition by monoclonal anti-pVIII antibodies by ELISA.
White bars represent native phages, black bars represent Neo-CAM
conjugated phages.
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highly immunogenic, a property that was used for their
application as carriers and boosters for vaccination
purposes [9-11]. High immunogenicity is counter-pro-
ductive for a drug carrying nanomedicine destined to
circulate in the body. In order to evaluate the immu-
nogenic properties of drug-carrying phages, BALB/c
mice were immunized intravenously or intraperitonealy
with 10
9 (low), 10
10 (medium) or 10
11 (high) Neo-
CAM carrying or native phages per dose. Three injec-
tions were performed at two weeks intervals. The mice
sera were examined for the presence and titer of anti-
phage antibodies by ELISA.A ss h o w ni nF i g u r e s3a n d
4 mice that were injected with drug-carrying Neo-
CAM phages showed much lower titers of anti-phage
antibodies than the mice received native phages. As
s h o w ni nF i g u r e3 ,w h e np h a g e sw e r ea d m i n i s t e r e dI V ,
serum anti phage titer rose in a dose dependent man-
ner and reached a maximum after the third injection
(a titer of 150000 for unconjugated and 40000 for
Neo-CAM carrying phages, a four-fold difference at
the maximal injected dose). Serum anti phage titer
declined after phage injection was completed, but
remained significant up to six months after the first
injection (a titer of 50000 for unconjugated and 16000
for Neo-CAM carrying phages at the maximal injected
dose). For the groups that were injected with fewer
phages, the fold differences in serum titer were similar
while the titers themselves were lower than the ones
reached at the maximal dose.
Figure 2 Toxicity evaluation of Neo-CAM conjugated phages. The open squares refer to native (unconjugated) phages, the filled squares
refer to Neo-CAM carrying phages. The single dosage of examined phages were injected intravenously (IV) or intraperitoneally (IP) at 10
9 phage/
dose (A, B), 10
10 phage/dose (C, D), 10
11 phage/dose (E, F). The average corresponds to 5 mice per group.
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Page 3 of 10Figure 3 ELISA analysis of anti-phage antibody titer in mice
serum. BALB/c mice were immunized with native or with Neo-CAM
carrying phages by intravenous (IV) injection. Three doses were
evaluated: low (10
9 phage/dose), medium (10
10 phage/dose) and
high (10
11 phage/dose). The sera samples were collected a week
following each injection (weeks 1, 3 and 5), and on the weeks 10
and 22 (n = 5 mice per group). Anti-phage serum titers were
determined by ELISA where serial serum dilutions were applied
onto phage-coated ELISA plate and detected using HRP-conjugated
goat anti mouse antibodies.
Figure 4 ELISA analysis of anti-phage antibody titer in mice
serum. BALB/c mice were immunized with native/Neo-CAM
carrying phages by intraperitoneal (IP) injection. Three doses were
evaluated: low (10
9 phage/dose), medium (10
10 phage/dose) and
high (10
11 phage/dose). The sera samples were collected a week
following each injection (weeks 1, 3 and 5), and on the weeks 10
and 22 (n = 5 mice per group). Anti-phage serum titers were
determined by ELISA where serial serum dilutions were applied
onto phage-coated ELISA plate and detected using HRP-conjugated
goat anti mouse antibodies.
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IP, the trend was similar but the titers were lower than
those received after injecting similar phage doses to the
mice IV. Serum anti phage titer rose in a dose depen-
dent manner and reached a maximum after the third
injection (a titer of 150000 for unconjugated and 15000
for Neo-CAM carrying phages, a ten-fold difference at
the maximal injected dose). Serum anti phage titer
declined after phage injection was completed, but
remained significant up to six months after the first
injection (a titer of 16000 for unconjugated and 5000
for Neo-CAM carrying phages injected at the maximal
dose). For the groups that were injected with fewer
phages, the fold differences in serum titer were similar,
with an exception that sera obtained during the two last
bleeds at low and medium injection doses showed low
titers with negligible differences between sera from mice
that were injected with unconjugated phages in compar-
ison to mice that were injected with Neo-CAM carrying
phages.
To evaluate the presence of anti-drug antibodies the
sera samples that were collected from mice immunized
with Neo-CAM carrying phages, a different ELISA was
carried out. Sera samples were examined for their ability
to bind native, neomycin-chloramphenicol conjugated
and neomycin only conjugated phages. We found that
s e r ao b t a i n e df r o mm i c et h a tw e r ei m m u n i z e dw i t h
native phages did not show preference in binding native
or drug-conjugated phages (Figure 5A), thus suggesting
there was no difference in phage adsorption to the
ELISA plate. The next step was to examine sera of mice
that were immunized with Neo-CAM carrying phages.
The assay demonstrated that antibodies presented in
mice sera samples were able to recognize conjugated as
well as un-conjugated phages to the same extent (Figure
5B) suggesting that no specific anti-drug antibodies
were raised in the mice.
An additional concern could be the immunogenicity
of the targeting antibody. While not evaluated experi-
mentally in this study, there a well-established solution
for that, of using humanized or human antibodies for
targeting.
The targeted drug-carrying phages, first introduced in
2006 [1] are a powerful tool for selective eradication of
pathogenic bacteria. Our group has demonstrated the
targeting ability of phage nanoparticle that was provided
by display of bacteria-specific peptide or antibody on
the phage surface. The conjugation of non-selective
drug to the targeted phage carrier via a labile linker
enabled the drug accumulation and action near the tar-
get bacteria that resulted in severe bacteria growth inhi-
bition in vitro [2]. Published in vivo phage therapy
studies may provide us with preliminary data concerning
the behavior of phages following in vivo administration.
However, while conventional research of phage therapy
could help us to elucidate the main principles of phage
in vivo behavior, there are many differences between
“classic” phage therapy and drug carrying approach that
may influence the phage behavior in animals and
humans. Earlier studies in classical phage therapy and
also in filamentous phage-based immunization protocols
established phages as a safe and non-toxic [9,12-14].
However, the drug our phage carry (chloramphenicol) is
not allowed in systemic administration because of its
side effects [8], raising concern that drug-mediated toxi-
city may be a limitation of our system. The toxicity eva-
luation of Neo/CAM carrying phage we carried out
showed that even the highest concentration of 10
11
phage/dose did not cause a significant toxic effect. We
assume that chloramphenicol lost its toxic properties as
a result of the conjugation, converting it into a “pro-
drug” s t a t ea sl o n ga si ti sc o n j u g a t e dt ot h ep h a g e
B
A
Figure 5 ELISA analysis of anti-drug immune response in
BALB/c mice immunized with native (A) or Neo-CAM carrying
(B) phages. Sera samples were obtained from mice immunized
with the highest phage concentration (10
11 phage/dose) following
the two boost injections and examined on their ability to bind
native (white), Neo-CAM conjugated (black) or Neo conjugated
(grey). Neither anti-chloramphenicol nor anti-neomycin antibodies
were detected in sera of immunized mice. The average corresponds
to 5 mice per group.
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release of the conjugated drug yields, even with clear-
ance rate neglected, a systemic concentration that is too
low to produce a harmful effect. This in general is an
advantage of a targeted drug-delivery system over non-
targeted ones.
The next subject of concern was the phage immuno-
genicity. Filamentous phages were known as highly
immunogenic and had been used as vaccine carries
while the vaccination with peptide-displaying phage
raised a high antibody titer against the displayed mole-
cule and more so, the phage itself [15]. The immuno-
g e n i cp r o p e r t i e sa r ep r o b a b l yc a u s e db yt h em u l t i p l e
repeats of pVIII protein on the phage surface and a
large size of a phage particle. Drug conjugation by EDC
chemistry targets the free carboxyl groups on phage
proteins that extremely influence the phage physical and
biological features. For example, EDC treated phages
cannot be recognized by commercial monoclonal anti-
phage antibodies, cannot be precipitated by PEG/NaCl,
a n dm o s t l yl o s et h e i ri n f e c t i v i t ya sd e m o n s t r a t e da b o v e .
Our results suggest that Neo-CAM carrying phages
were far less immunogenic in comparison to native
phages. The repeated injections of drug-conjugated
phages resulted in reduced anti-phage antibody titer
(50,000 for intravenous and 18,000 for intraperitoneal
injection), while the antibody titer for un-conjugated
phage injections reached 150,000. The sera samples that
were collected 1.5 and 5 months after the last injection
reported the extinguishing of anti-phage titer for both
conjugated and un-conjugated treatments. The intraper-
itoneal administration demonstrated lower absolute
titers for drug-carrying drugi nc o m p a r i s o nt on a t i v e
phage, suggesting this administration route may be
more appropriate for further study. Based on the
described results, we propose that the reduced immuno-
genicity of drug-carrying phage treatment was achieved
due to neomycin, used for chloramphenicol conjugation.
Neomycin was chosen as a hydrophilic agent that can
mediate between the phage platform and hydrophobic
drug (chloramphenicol). The conjugation of this amino-
glycoside antibiotic probably provides the “sugar envel-
ope” for a phage particle turning it into much less
immunogenic. In addition, the immunization of BALB/c
mice with directly conjugated drug (without aminogly-
coside linker) resulted in induced anti-phage antibody
titer similar to un-conjugated phage treatment (our
unpublished results). It is widely known that sugars and
amino-related coating (such as PEGylation and poly
(amino acid)s conjugation) of immunogenic protein
reduce the immune response against it and improve its
pharmacokinetic features [16-19]. We suggest that ami-
noglycoside conjugation to proteins provides its “shield-
ing” from the immune system similar to these reported
effects. In addition, we demonstrated that the drug pre-
sentation on the phage carrier did not lead to anti-drug
immune response against neomycin or chloramphenicol.
We propose that one or both of the following models
may account for the reduced immunogenicity of tar-
geted Neo-Cam carrying phages:
Chloramphenicol molecules are slowly released from
t h ep h a g es u r f a c eb ys e r u me s t e r a s e s .A sar e s u l t ,t h e
phage is constantly changing and does not present a
continuing stimulus to the immune system that as a
result gets “confused and unfocused”.
Similarly to reduction of immunogenicity of biophar-
maceuticals by PEG [20], neomycin remains on the
phage surface and as it was implied above, it might
shield the phage particle from the immune system.
The reduced immunogenicity of drug-carrying phages
should allow a number of sequential treatments (repeat
therapy) without severe side effects that is highly signifi-
cant for anti-bacterial treatments.
Comparative pharmacokinetics of Neo-CAM carrying
phage and native phage in mice serum
Previous studies on native filamentous phage pharmaco-
kinetic properties in mice demonstrated rapid removal
of phage particles from the circulation 5 to 15 min fol-
lowing intravenous injection [21]. Another study sug-
gested that bacteriophages’ half-life in mouse serum is
about 4 hours [22]. To determine the half-life of drug-
carrying phage the BALB/c mice were injected with
either native or Neo-CAM carrying phages and blood
samples were taken at varying time points following
injection. In order to evaluate the phage particles con-
centration in the samples, two different approaches were
chosen: CFU recovery and Real-Time PCR.
CFU recovery is widely used for phage quantification
while the phage amount is calculated corresponding to
infective phage particles. Bacteriophages following the
drug conjugation by EDC chemistry partially lose their
infectivity, thus complicating interpretation of the
results. According to the phage quantification based on
colony forming units (CFU) recovery, Neo-CAM carry-
ing phages remain in the bloodstream with a half life of
48 min (almost 60% more the time of native phages)
(Figure 6A). The total clearance of phage particles from
blood circulation required up to 24 hours. This result
further suggests that Neomycin “sugar coating” of the
phage nanoparticles may serve as an efficient anti-
immunogenic agent, which can reduce immune
response, by shielding a nanoparticle (liposomes or
phage) from both the immune system and the RES sys-
tem which is primarily responsible for removal of
phages from the circulation [22].
To confirm the previous result, Real-Time PCR was
conducted to quantify phage DNA in serum samples.
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drug conjugation process, the phage DNA remained
unaffected. We developed a Real-Time PCR assay for
phage DNA quantification in serum samples as an accu-
rate method for determination of phage DNA concen-
tration. Our results suggest that Neo-CAM phages
remain longer in the circulation than the unconjugated
phages. The differences (39 min for Neo-CAM carrying
phage in comparison to 34 min for native phage parti-
cles (Figure 6B)) were similar but not identical to those
found by CFU determination. These results further
demonstrated that Neo-CAM conjugation to phage coat
proteins influenced the phages’ pharmacokinetic proper-
ties and increased its serum half-life in mice.
It is intriguing that the immunogenicity of Neo-CAM-
conjugated phages is reduced compared to native phages
while their serum half-life in increased. Presently it is
not to what extent anti-phage antibodies rise as a result
of direct stimulation of phage-specific B-cells, or
processing and presentation of phage epitopes on pro-
fessional antigen-presenting cells (APCs) (such as the
macrophages and dendritic cells that are part of the RES
system that removed phages from the body) plays a
dominant role. Our results may suggest that APCs play
a key role in the development of anti-phage antibodies,
and the “sugar coating” that causes the Neo-Cam-carry-
ing phages to be removed with different kinetics also
attenuate antigen presentation and antibody production.
At this time, such an assumption is highly speculative.
The evaluation of in vivo activity of targeted drug-car-
rying phages would be the next determining step in
technique development. Our preliminary results on Sta-
phylococcus aureus bacteria systemic infection of BALB/
c mice demonstrated the partial recovery followed by
single injection of anti-S. aureus Neo-CAM carrying
phages in comparison to 100% lethality in control group
(unpublished data).
Conclusion
There is a renaissance of interest in the antimicrobial
potential of phages as more pathogens become multiply
antibiotic resistant [23]. While most efforts in the field
of phage therapy use “classical” approached where the
target bacteria are killed by virtue of the phage acting as
a natural killer of the bacterial host, the approach of tar-
geted drug-carrying phage nanomedicines we pioneered
is different. Our phages are rendered non-infective by
the drug conjugation chemistry, and the natural phage-
host specificity is replaced by the target specificity con-
ferred by the targeting moiety that is displayed on the
phage. Still, any therapeutic application of phages will
have to involve mitigation of harmful properties such as
toxicity and immunogenicity.O u rs t u d yd e m o n s t r a t e d
that drug-carrying phages, and in particular phages that
carry chloramphenicol via an aminoglycoside linker
were safe and feebly immunogenic in a small animal
model and would be able to continue its way to therapy.
Future work will focus on the targeting improvement
which is crucial for the potency and selectivity of the
conjugated drug. The other research direction can be
the finding an alternative drug release method based on
contact with treated pathogen that can greatly improve
the therapeutic activity of the approach in vitro as well
as in vivo.
Methods
Phage preparation
For propagation of fUSE5 filamentous phage, a phage
infected E. coli (DH5a strain) colony was inoculated
into 0.5 liter of 2 × YT medium supplemented with 12.5
μl/ml tetracycline and grown overnight with shaking
(250 rpm) at 30°C. The culture was centrifuged and fil-
tered (to eliminate remaining bacteria) through a 0.45
A
30 min
48 min
34 min
39 min
B
Figure 6 Analysis of Neo-CAM carrying vs. native phages blood
pharmacokinetics in mice: recovery of colony forming units
(CFU) (A) or phage DNA quantification by Real-Time PCR (B).
BALB/c mice were injected with 10
11 native/Neo-CAM carrying
phages in 200 μL sterile PBS and blood samples were collected at
the indicated time points. (A) For CFU determination the serum
samples were incubated with E. coli bacteria, and then plated on
agar supplemented with appropriate antibiotics and colony forming
units counted the next day. (B) For phage DNA quantification the
serum samples were amplified by Real-Time PCR and phage DNA
amount was calculated using the calibration curve. The % phage
concentrations were calculated relatively to the phages found at the
8 min time point.
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PEG/NaCl (20% polyethylene 6000, 2.5 M NaCl) was
added to the supernatant, mixed well and incubated
overnight at 4°C for phage precipitation. The phage-pre-
cipitates were collected by centrifugation at 6000 rpm
for 30 min at 4°C, resuspended in sterile water at a final
concentration of 5 × 10
13 PFU/ml, filtered and stored at
4°C.
Drug conjugation
The chloramphenicol prodrug was synthesized and con-
jugated to the phage particles via a neomycin linker as
described [2]. The procedure included drug conjugation
using EDC chemistry that provided the coupling of the
exposed carboxyl side chains on the phage coat and
neomycin primary amine. For removal of free drug
excess and reduction of endotoxin content, the un-con-
jugated as well as the drug conjugated phages were dia-
lyzed by two sequential steps against 1000 volumes of
0.3 M NaCl at 4°C for 16 hours each. Phages that carry
chloramphenicol via a neomycin linker are referred to
as “Neo-CAM phages”.
Phage quantification by live titration
DH5aF’ strain of E. coli bacteria were grown in 2 × YT
media till A600 nm reached 0.8. Then 90 μl of bacteria
were infected with 10 μl phage dilutions and incubated
1 hour at 37°C. Drops of 10 μl of incubated bacteria
were plated onto agar plates supplemented with 12.5 μl/
ml tetracycline and grown at 37°C overnight to develop
colonies of phage infected cells. Phage quantity was cal-
culated according to the resistant bacteria colonies num-
ber multiplied by phage dilution in the drop.
Mouse toxicity evaluation
Animal experimentation was carried out with approval
of the Tel-Aviv University IRB. Female BALB/c mice (8-
10 weeks old, ~20 gr, 5 mice in each group) were given
a single injection intravenously (tail vein) or intraperito-
nealy of Neo-CAM phage or native (naked) phage. The
phages were diluted in phosphate buffer saline (PBS) to
10
9,1 0
10 or 10
11 phages/dose and injected in total
volume of 200 μl. Mice were monitored for weight loss
or death for 8 days after infection.
Immunogenicity assay
Female BALB/c mice (8-10 weeks old, ~20 gr, 5 mice
per group) were immunized with 10
9,1 0
10 or 10
11 Neo-
CAM conjugated or native phages per dose. Phages
were diluted to the desired concentration in phosphate
buffered saline (PBS) in a final volume of 200 μl. Two
routes of administration were evaluated: intravenously
(tail vein) and intraperitonealy. Mice received the injec-
tions 3 times on weeks: 0, 2, 4 and were bleed from the
orbital vein on the weeks: 1, 3, 5, 10 and 22. The blood
samples were clotted on ice for 1 hour, than centrifuged
and sera were collected and stored at -20°C.
ELISA
Drug-conjugated (Neo-CAM) a n du n c o n j u g a t e dp h a g e s
were evaluated for their recognition by monoclonal anti-fd
antibodies. For that purpose, 96-well ELISA plate was
coated with polyclonal mouse anti-phage serum (diluted
1:1500 in PBS) for 1 hour at 37°C and blocked with 3%
skim milk in PBS for 1 hour at 37°C. The plate was
washed with PBS containing 0.05% (v/v) tween 20 (PBST)
and incubated with Neo-CAM conjugated or native phage
diluted in PBST. Following 1 hour incubation at room
temperature, the plates were washed three times with
PBST and incubated with an HRP-conjugated monoclonal
mouse-anti-PVIII antibody (diluted 1:5000 in PBST) for 1
hour at room temperature. Followed by 3 times wash in
PBST, the plates were developed with the chromogenic
substrate TMB and color development was terminated
with 1 M H2SO4. The plates were read at 450 nm.
For determination of anti-phage antibody titer in sera
of immunized mice, the 96-well ELISA plate was coated
with 10
10 native phage suspension in PBS/well for 2
hours 37°C followed by blocking with 3% skim milk in
PBS overnight at 4°C. All subsequent steps were per-
formed at room temperature. Dilutions (from 1:200) of
sera samples in PBS were applied onto plates and incu-
bated for 1 hour. The plates were washed three times
with PBST, followed by incubation with an HRP-conju-
gated goat-anti-mouse antibody (diluted 1:5000 in
PBST) for 1 hour, than washed 3 times in PBST. The
plates were developed as described above.
In order to estimate the presence of anti-drug antibo-
dies that may have been raised during the mice immuni-
zation, 96-well ELISA plates were coated with 10
10 phage
suspension in PBS/well of the following phages: native
(un-conjugated), Neo-CAM carrying, or Neo only carry-
ing for 2 hours at 37°C. Plates were blocked with 3%
s k i mm i l ki nP B Sa t4 ° Co v e r n i g h tf o l l o w e db yt h r e e
washes in PBST. 3-fold dilutions (from 1:600) of sera
samples (obtained from mice immunized with the highest
(10
11 phages/dose) intravenous injections of Neo-CAM
carrying and native phages) in PBS were applied onto
plate and were incubated for 1 hour. The following steps
were executed exactly as the previously described assay.
All the ELISA experiments were carried out in dupli-
cates or triplicates at least 3 independent times during
the study.
Determination of Neo-CAM phage vs. native phage
circulation half life time in mice
To evaluate and compare the blood pharmacokinetic
properties of Neo-CAM phage and native phage (that
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old, ~20 g, 5 mice in group) were given a single intrave-
nous dose of 10
11 Neo-CAM/native phage by injection
into the tail vein. Blood samples were collected from the
orbital vein at 8, 60, 120, 240 and 480 min and 24 hours
after injection. Each mouse was bled two or three times,
so different mice were used to collect data for the var-
ious time points. Subsequent to clotting the blood sam-
ples on ice the serum concentrations of phages were
determined by CFU recovery (live titration) or Real-
Time PCR.
Colony forming units (CFU) quantification in mouse
serum
For CFU determination, 90 μLo fF ’ E. coli TG-1 cells
were infected with 10 μL of mouse serum dilutions. The
infected bacteria were incubated 1 hour at 37°C and
then plated on agar plate supplemented by 20 μg/ml tet-
racycline. The number of tetracycline-resistant colonies
or colony forming units (CFU) was counted the next
day. Phage concentration was calculated according to
CFU number in the serum dilution.
Phage quantification by Real-Time PCR
Real-Time PCR was used to quantify the phage DNA
particles in serum. Real-Time PCR was performed as
follows, 1 μL of serum diluted 1:100 in PBS, 500 nM
fUSE5-RT (5’- CTTTGAACGAGGACAGATGC -3’) and
P5-BsrGI-For (5’- TCGTCAGGGCAAGCCTTATTC -3’)
primers, qPCR Supermix-UDG (containing: SYBR Green
I fluorescent dye, platinum TaqDNA polymerase,
MgCl2, dNTPs, uracil-DNA glycosylase (UDG), reaction
buffer) (Invitrogen). The reaction conditions were: 95°C
for 2 min, 45 cycles of 95°C for 15 sec and 60°C for 30
sec, final extension 60°C for 5 min. The reaction was
carried out and analyzed as recommended by the sup-
plier (Applied Biosystems). Fl u o r e s c e n c ed a t aw e r ec o l -
lected at the end of each 60°C annealing step. The
sample was designated positive when there was an expo-
nential increase in fluorescence during the first 30 cycles
of PCR amplification (crossing point, ≤ 30). Samples
with crossing points of > 30 cycles were determined as
<1 0
6 phage/ml. Phage concentration in a sample was
determined according to a calibration curve of Neo-
CAM/native phage at increasing concentrations (10
6-
10
11 phage/ml).
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